Material Safety Data Sheet
______________________________________________________________________________________________
SDS # : A-0009 Dry Imager -Black Issuing Date 1983-01-25 Revision Date 2011-07-27 Version 1 1. PRODUCT AND COMPANY IDENTIFICATION Trade Name:
2020, 2300, 2350, 2600, 2700, 3100, 3100 LDC, 3103,3107, 3109, 3300, 3400, 3450, 3700, 8040, 8040 SeriesEP, 4045, XP10, XP10E, XP12, XP12E, XP24
Part No. 006R00099, 006R00134, 006R00223, 006R00224, 006R00400, 006R00401, 006R00410, 006R00402, 006R00403, 006R90123, 006R00047, 006R00049, 006R00033, 006R00067, 006R00068, 006R00072, 006R00074, 006R00091, 006R00100, 006R00101, 006R00189, 006R00233, 006R00508 Pure substance/preparation Identified uses Manufacturer Emergency telephone
Safety Information (800)828-6571Health Emergency (585)422-2177Chemical Emergency only (Chemtrec) (800)424-9300or (703)527-3887 (collect outside the US or Canada)
Emergency Overview
The product contains no substances which, in the form utilized and at their given concentrations, are considered to
Appearance Physical state Potential Health Effects Principle Routes of Exposure Acute toxicity Inhalation Ingestion Chronic effects Chronic toxicity
No known effects under normal use conditions. Repeated or prolonged inhalation maycause irritation of the respiratory tract as can occur with the inhalation of any non- toxicdust. Minimum respiratory or eye irritation may occur as with exposure to large amounts ofany non-toxic dust. Main symptoms
Overexposure may cause:mildrespiratory irritation
Aggravated Medical Conditions None under normal use conditions SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
Environmental hazard
See Section 12 for additional Ecological Information
Risk Phrases
3. COMPOSITION/INFORMATION ON INGREDIENTS
Chemical Name General advice
When symptoms persist or in all cases of doubt seek medical advice. Show this materialsafety data sheet to the doctor in attendance. Eye contact
Immediately flush with plenty of water. After initial flushing, remove any contact lenses andcontinue flushing for at least 15 minutes
Skin contact Inhalation Ingestion
Rinse mouth with water and afterwards drink plenty of water or milk
Notes to physician Protection of first-aiders
No special protective equipment required. Flammable properties
Not flammable. Will not readily ignite. Flash point Suitable extinguishing media
Use water spray or fog; do not use straight streams, Foam
Unsuitable extinguishing media
Do not use a solid water stream as it may scatter and spread fire
Hazardous combustion products
Hazardous decomposition products due to incompletecombustion, Carbon oxides, Nitrogen oxides (NOx)
Explosion Data Sensitivity to Mechanical Impact Sensitivity to Static Discharge
Fine dust dispersed in air, in sufficient concentrations, and in thepresence of an ignition source is a potential dust explosionhazard. Specific hazards arising from the chemical Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
Protective Equipment and Precautions for Firefighters In the event of fire and/or explosion do not breathe fumes. Wear fire/flame resistant/retardant clothing. Use self-contained pressure-demand breathing apparatus if needed to prevent exposure to smoke or airborne toxins. NFPA 704 Consumer use Health Hazard Flammability Stability Special hazard Bulk Packaging Health Hazard Flammability Stability Special hazard Personal Precautions Environmental Precautions
Refer to protective measures listed in Sections 7 and 8. Methods for containment Methods for cleaning up
Prevent dust cloud. Sweep up or vacuum up spillage and collect in suitable container fordisposal. Use non-sparking tools and equipment. Other Information
See Section 12 for additional information
Advice on safe handling
Handle in accordance with good industrial hygiene and safety practiceAvoid dust accumulation in enclosed spacePrevent dust cloud
Technical measures/Storage
Keep container tightly closed in a dry and well-ventilated place
conditions Hygiene measures Industrial User
Do not eat, drink or smoke when using this productWash hands before eating, drinking, chewing gum, using tobacco, or using toiletWash hands before breaks and at the end of workdayProvide regular cleaning of equipment, work area and clothing
Exposure guidelines Product information ACGIH TLV TWA ACGIH TLV TWA OSHA PEL TWA OSHA PEL TWA Xerox Exposure Limit Xerox Exposure Limit SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
Other Information The results obtained from a Xerox sponsored Chronic Toner Inhalation Study demonstrated no lung changes in rats for the lowest (1mg/m3 ) exposure level (the level most relevant to potential human exposure). A very slight degree of fibrosis was noted in 25% of animals at the middle (4mg/m3 )exposure level, while a slight degree of fibrosis was noted in all the animals at the highest (16mg/m3 ) exposure level. These findings are attributed to "lung overloading", a generic response to excessive amounts of any dust retained in the lungs for a prolonged period. This study was conducted using a special test toner to comply with an EPA testing protocol. Biological standards This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies Occupational Exposure Controls Engineering measures Industrial use
Avoid dust formationEnsure all equipment is electrically grounded before beginning transfer operationsProvide appropriate exhaust ventilation at places where dust is formed
Personal Protective Equipment Consumer use
These recommendations apply to the product as supplied
Respiratory protection
No special protective equipment required. Eye/Face protection
No special protective equipment required. Skin and body protection
No special protective equipment required. Hand protection Industrial use
In case of insufficient ventilation:Wear protective eyewear (goggles)Effective dust mask
Appearance Odor threshold Physical state Flash point point/range Softening point Autoignition temperature Flammability Limits in Air Explosive properties
Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignitionsource is a potential dust explosion hazard
Vapor pressure Vapor density SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
Water solubility Viscosity Partition coefficient Evaporation rate Melting point/range Freezing point Specific gravity Reactivity
No dangerous reaction known under conditions of normal use
Stability Incompatible products Conditions to Avoid
Prevent dust cloud, Fine dust dispersed in air, in sufficient concentrations, and in thepresence of an ignition source is a potential dust explosion hazard
Hazardous Decomposition Products None under normal use Hazardous polymerization Hazardous reactions Acute toxicity Product information Irritation LD50 Oral: LD50 Dermal: LC50 Inhalation: Chronic toxicity Product information Chronic effects
No known effects under normal use conditions. Repeated or prolonged inhalation maycause irritation of the respiratory tract as can occur with the inhalation of any non- toxicdust. Minimum respiratory or eye irritation may occur as with exposure to large amounts ofany non-toxic dust. Carcinogenicity
See "Other Information" in this section. Chemical Name Other toxic effects Product information Sensitization Mutagenic effects Target organ effects Other adverse effects Aspiration Hazard SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
Other information The IARC (International Agency for Research on Cancer) has listed carbon black as "possibly carcinogenic to humans". The classification is based on studies evaluating pure, "free" carbon black. In contrast, toner is a formulation composed of specially prepared polymer and a small amount of carbon black (or other pigment). In the process of making toner, the small amount of carbon black becomes encapsulated within a matrix. Xerox has performed extensive testing of toner, including a chronic bioassay (test for potential carcinogenicity). Exposure to toner did not produce evidence of cancer in exposed animals. The results were submitted to regulatory agencies and published extensively. Ecotoxicity The environmental impact of this product has not been fully investigated. However, this preparation is not expected to present significant adverse environmental effects. Waste Disposal Methods
This material, as supplied, is not a hazardous waste according to Federal regulations (40CFR 261). This material could become a hazardous waste if it is mixed with or otherwisecomes in contact with a hazardous waste, if chemical additions are made to this material, orif the material is processed or otherwise altered. Consult 40 CFR 261 to determine whetherthe altered material is a hazardous waste. Consult the appropriate state, regional, or localregulations for additional requirements
Contaminated packaging
Dispose of in accordance with local regulations.
This material is not subject to regulation as a hazardous material for shipping. International Inventories TSCA U.S. Federal Regulations SARA 313 Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372. SARA 311/312 Hazard Categories Acute Health Hazard Chronic Health Hazard Fire Hazard Sudden Release of Pressure Hazard Reactive Hazard Clean Water Act This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42). Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61) This product does not contain any substances regulated as hazardous air pollutants (HAPS) under Section 112 of the Clean Air Act Amendments of 1990. SDS # : A-0009 Dry Imager -Black
______________________________________________________________________________________________
CERCLA This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material. TSCA TSCA 12b does not apply to this product. U.S. State Regulations California Proposition 65 This product does not contain any Proposition 65 chemicals. Chemical Name California Prop. 65 U.S. State Right-to-Know Regulations Canada This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the MSDS contains all the information required by the CPR. WHMIS Hazard Class Not subject to WHMIS classification Issuing Date Revision Date Revision Note Disclaimer The information provided on this MSDS is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered as a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other material or in any process, unless specified in the text
I. INTRODUCTION The named End-Payor plaintiffs seek class certification of a class comprised of individual consumers, third-party payors (“TPPs”), union plan sponsors, and insurance companies that purchased or provided reimbursements for Nexium in those states that permit such an action. See Corrected Consol. Am. Class Action Compl. & Demand Jury Trial (“End-Payors’ Compl.”)
CYPROHEPTADINE, PIZOTIFEN AND AMITRYPTILINE AS PROPHYLACTIC THERAPY IN CYCLIC VOMITING SYNDROME S. Martinazzi, M. Fuoti, M. Brusati, A. Ravelli University Department of Pediatrics, Children’s Hospital, Spedali Civili – Brescia (Italy) BACKGROUND AND AIM. Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder of unknown origin that causes severe recurrent attack